AcroImmune Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Investors
  • 1

AcroImmune General Information

Description

Provider and developer of immunotherapy drugs designed for malignant tumor and inflammation disease. The company provides first-in-class drugs and best-in-class drugs, enabling tumor patients with treatments.

Contact Information

Website
www.acroimmune.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Room 602, Building 1, Phase III
  • Standard Industrial Unit, Guangzhou International Biological Island
  • Guangzhou, Guangdong 510320
  • China
+86 020
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 602, Building 1, Phase III
  • Standard Industrial Unit, Guangzhou International Biological Island
  • Guangzhou, Guangdong 510320
  • China
+86 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AcroImmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 25-Sep-2024 Completed Clinical Trials - General
5. Early Stage VC 22-Oct-2021 Completed Clinical Trials - General
4. Early Stage VC 24-Jun-2021 Completed Clinical Trials - General
3. Early Stage VC (Series B) 11-Sep-2020 Completed Clinical Trials - General
2. Early Stage VC 16-Apr-2019 Completed Pre-Clinical Trials
1. Seed Round 15-Oct-2018 Completed Startup
To view AcroImmune’s complete valuation and funding history, request access »

AcroImmune Patents

  • 14

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

AcroImmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023371361-A1 Cd24 binding protein and use thereof Pending 01-Nov-2022
EP-4613779-A1 Cd24 binding protein and use thereof Pending 01-Nov-2022
US-20260184806-A1 Cd24 binding protein and use thereof Pending 01-Nov-2022
US-20260325638-A1 Cd24 binding protein and use thereof Pending 01-Nov-2022
WO-2024093882-A1 Cd24 binding protein and use thereof Inactive 01-Nov-2022 C07K16/2896
To view AcroImmune’s complete patent history, request access »

AcroImmune Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
3E Bioventures (China) Venture Capital Minority
GBA Capital Association Venture Capital Minority
GF Xinde Investment Management PE/Buyout Minority
HM Venture Partners Venture Capital Minority
Huangpu Talent Services Corporation Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

AcroImmune FAQs

  • When was AcroImmune founded?

    AcroImmune was founded in 2018.

  • Where is AcroImmune headquartered?

    AcroImmune is headquartered in Guangzhou, China.

  • What industry is AcroImmune in?

    AcroImmune’s primary industry is Drug Discovery.

  • Is AcroImmune a private or public company?

    AcroImmune is a Private company.

  • What is AcroImmune’s current revenue?

    The current revenue for AcroImmune is .

  • How much funding has AcroImmune raised over time?

    AcroImmune has raised $56M.

  • Who are AcroImmune’s investors?

    3E Bioventures (China), GBA Capital Association, GF Xinde Investment Management, HM Venture Partners, and Huangpu Talent Services are 5 of 8 investors who have invested in AcroImmune.

  • When was AcroImmune acquired?

    AcroImmune was acquired on 25-Sep-2024.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process